This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Alexion moves to dismiss EmblemHealth's US antitrust claims over Soliris

( August 5, 2025, 12:00 GMT | Official Statement) -- MLex Summary: Alexion Pharmaceuticals moved to dismiss EmblemHealth's US antitrust claims over Soliris, telling a Massachusetts federal judge that Emblem's claims over Alexion's patent litigation against Amgen and Samsung Bioepis challenge conduct that's immune from antitrust liability under the Noerr-Pennington doctrine. Emblem's claim that the patent challenges were shams meant to delay entry of biosimilar competitors for Soliris runs up against facts showing Alexion's success in obtaining a lawful settlement agreement with Samsung Bioepis, and that it never asserted its patents against Amgen, Alexion said in its motion-to-dismiss filed to the District of Massachusetts. Emblem also lacks standing to plead claims based on alleged fraud on the US Patent and Trademark office, and has not stated an antitrust claim for product-hopping over Alexion's introduction of its Ultomiris product, the motion said.See attached document: ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections